NEW YORK (
CHANGE IN RATINGS
Pieris Jumps on Grant for Drug to Treat Lung Scarring From COVID
Pieris received a grant of $17 million from the Bavarian Ministry of Economic Affairs for a drug to treat lung scarring in COVID sufferers.
upgraded at Oppeneheimer to Outperform from Perform, Oppenheimer said. $16 price target. Upside once macro improved.
STOCK COMMENTS / EPS CHANGES
target raised at Lazard.Shares of AMZN now seen reaching $275, according to Lazard. Company remains leveraged to continued e-commerce growth and can generate 25% annual growth in its core business. Buy rating.
estimates, target reduced at BofA/Merrill. CIEN estimates were cut through 2014, Bank of America/Merrill Lynch said. Estimates also lowered, given the company's new guidance. Buy rating and new $17 price target.
Ciena numbers cut at UBS. Shares of CIEN now seen reaching $14, UBS said. Estimates also lowered as results and outlook generally disappoint. Neutral rating.
numbers raised at Jefferies. Shares of COST now seen reaching $89, Jefferies said. Estimates also raised on strong August results. Hold rating.
estimates, target boosted at Credit Suisse.Shares of ESL now seen reaching $72, according to Credit Suisse. Estimates also upped, given the company's new guidance. Outperform rating.
target cut at BofA/Merrill to $23. Social media stocks have performed poorly recently around share lockup expirations. Neutral rating.
Facebook estimates, target reduced at BMO.FB estimates were cut through 2014, BMO Capital said. Channel checks suggest that advertising prices are falling. Underperform rating and new $15 price target.
estimates, target raised at Credit Suisse.Shares of SPLK now seen reaching $42.50, according to Credit Suisse. Estimates also increased, as the company is seeing higher demand for larger deals. Outperform rating.
Splunk numbers raised at UBS.Shares of SPLK now seen reaching $36, UBS said. Estimates also increased on strong 2Q results. Neutral rating.
estimates, target reduced at Piper.ZUMZ estimates were cut through 2013, Piper Jaffray said. Company is seeing slower sales growth. Neutral rating and new $34 price target.
Zumiez target lowered at Jefferies.Shares of ZUMZ now seen reaching $33, Jefferies said. Cautious on the second half. Hold rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.